Navigation Links
NeoGenomics Announces Results for the 3rd Quarter 2007
Date:11/14/2007

FORT MYERS, Fla., Nov. 14 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a premier, high-complexity cancer genetics laboratory, today announced its results for the third quarter of FY 2007. Significant accomplishments during the third quarter and for the first nine months of the year included the following:

Third Quarter 2007 Accomplishments:

-- 95% year-over-year increase in revenues in Q3 07 vs. Q3 06

-- 33% sequential growth in revenue from Q2 07

-- Completion of the first three contract assignments for our new Contract

Research Organization (CRO) in California

-- Achieved participating provider status with six more insurance plans

-- Roll-out of NeoFlow(TM), a virtual flow cytometry analysis tool with

custom reporting

Year-to-Date Accomplishments:

-- 64% year-over-year increase in revenues in YTD 9 Months FY 07 vs. 9

Months FY 06

-- Continued rapid expansion of NeoFISH(TM) customers

-- Expansion of Sales & Marketing staff to 16 professionals from 4 at end

of Q3 06

During the third quarter, we increased revenues by approximately 95% to $3.12 million from $1.60 million during Q3 06, largely as a result of a greater number of tests being performed for our customers. Average revenue per requisition increased by approximately 2% to $683.01 in Q3 07 from $668.01 in Q3 06. Average revenue per test increased by a robust 14% to $552.30 in Q3 07 from $484.10 in Q3 06. Gross profit increased by approximately 82% to $1.60 million in Q3 07 from $880,000 in Q3 '06. We experienced some compression in our gross margin percentage on a year-over-year basis, because the popular PathVysion breast cancer FISH test is only a two probe test which has relatively high supply costs and significantly lower average reimbursement than other FISH tests and, we are doing significantly more of these tests this year. On a sequential basis, however, our gross mar
'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants from ... Lead Academic Participating Site in its new National ... a select groups of investigators charged with distributing resources ... The NCTN grant system reflects recommendations from a ... to achieve four goals:, Faster design, launch, ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... how low doses of arsenic, such as the levels found ... affect human physiology. In a paper published online on Dec. ... report that three different steroid hormones all show similar responses ... of arsenic on how these hormones function. ,"Since ...
... by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park ... chronic lymphocytic leukemia (CLL) or diseases that no longer ... the therapy. The results of this study were published ... Clinical Oncology. ,"Chronic lymphocytic leukemia is ...
... arithmetic or to make change for a dollar. She is ... can’t write down her name clearly, nor can she cross ... person. She can sing like a nightingale although her IQ ... she knows hundreds of songs in Italian, German French, Macedonian, ...
... U.S firm Schwarz has found to be potential in reducing ... drugs - the company said on Monday following the results ... the 485-patient study were presented at the North American Regional ... 200-mg dose of the drug, lacosamide, had 14.4 percent fewer ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... of obesity, as a causative factor for breast cancer. It ... factor for cancer, heart disease, stroke and diabetes. Scientists have ... breast cancer. ,Latest research has indicated that having ... female hormones, the presence of which elevates the risk of ...
Cached Medicine News:Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 2Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 3Health News:Heavenly Notes from a Life Etched With Disability: The Strangest Song 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... IRVINE, Calif., May 17, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced that it ... The acquisition of Cardiogenesis adds to ... the treatment of diffuse coronary artery disease and severe ...
... the second consecutive year, the Exergen temporal artery thermometer ... the product, according to Nielsen and Information Resources Inc. ... national brands and private label products, were compared. Along ... has risen to 20 percent of all thermometers for ...
Cached Medicine Technology:CryoLife Announces Completion of Acquisition of Cardiogenesis 2CryoLife Announces Completion of Acquisition of Cardiogenesis 3CryoLife Announces Completion of Acquisition of Cardiogenesis 4CryoLife Announces Completion of Acquisition of Cardiogenesis 5CryoLife Announces Completion of Acquisition of Cardiogenesis 6CryoLife Announces Completion of Acquisition of Cardiogenesis 7CryoLife Announces Completion of Acquisition of Cardiogenesis 8CryoLife Announces Completion of Acquisition of Cardiogenesis 9CryoLife Announces Completion of Acquisition of Cardiogenesis 10
... ACL 8000 is an easy-to-use, automated system ... array of assays for managing hemostatic disordersincluding ... S. Also offers reflex and rerun testing ... it's backed by our high-quality service to ...
... ACCUNET Embolic Protection System is designed to ... control when performing carotid stenting interventions. The ... filter system that utilizes rapid exchange technology ... the filter during catheter manipulations. It is ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: